Table of Contents

1 Report Prologue 9
2 Market Introduction 13
2.1 Introduction 13
2.2 Scope of Study 13
2.3 Research Objective 13
2.4 Assumptions & Limitations 14
2.4.1 Assumptions 14
2.4.2 Limitations 14
2.5 Market Structure 15
3 Research Methodology 16
3.1 Research Process 16
3.2 Primary Research 17
3.3 Secondary Research 17
4 Market Dynamics 18
4.1 Introduction 18
4.2 Drivers 18
4.2.1 Growing Incidence Number of Contagious and Non-Contagious Diseases 18
4.2.2 Improving Medical Device Regulation 18
4.2.3 Increasing Inclination Towards Home Healthcare 19
4.2.4 Increasing Prevalence of Diabetes 19
4.3 Restraint 20
4.3.1 Risk Associated with blood transfusion 20
5 Market Factor Analysis 21
5.1 Porter's Five Forces Model 21
5.1.1 Bargaining Power of Suppliers 21
5.1.2 Bargaining Power of Buyers 22
5.1.3 Threat of New Entrants 22
5.1.4 Threat of Substitutes 22
5.1.5 Intensity of Rivalry 22
5.2 Supply Chain Analysis 22
6 Global Safety Lancet Market, By Type 25
6.1 Introduction 25
6.2 Push Button Safety Lancet 26
6.3 Pressure Activated Safety Lancet 28
6.4 Side Button Safety Lancet 29
7 Global Safety Lancet Market, By End User 30
7.1 Introduction 30
7.2 Hospitals & Clinics 32
7.3 Diagnostic Centers and Pathology Laboratories 33
7.4 Home Diagnostics 33
7.5 Other End Users 34
8 Global Safety Lancet Market, By Region 35
8.1 Introduction 35
8.2 North America 37
8.2.1 The U.S. 39
8.2.2 Canada 40
8.3 Europe 42
8.3.1 Germany 45
8.3.2 France 46
8.3.3 UK 47
8.3.4 Italy 48
8.3.5 Spain 49
8.3.6 Rest of Europe 50
8.4 Asia-Pacific 51
8.4.1 Japan 54
8.4.2 China 55
8.4.3 India 56
8.4.4 Republic of Korea 57
8.4.5 Rest of Asia-Pacific 58
8.5 Middle East & Africa 59
8.5.1 UAE 62
8.5.2 Egypt 63
8.5.3 Saudi Arabia 64
8.5.4 Rest of Middle East & Africa 65
9 Competitive Landscape 66
9.1 Pricing of Lancets 67
10 Company Profile 68
10.1 F. Hoffmann-La Roche AG 68
10.1.1 Overview 68
10.1.2 Product/Business Segment Overview 68
10.1.3 Financial Updates 69
10.1.4 Key Developments 70
10.1.5 SWOT Analysis 71
10.2 Becton, Dickinson and Company 72
10.2.1 Overview 72
10.2.2 Product/Business Segment Overview 72
10.2.3 Financial Updates 72
10.2.4 Key Developments 74
10.2.5 SWOT Analysis 75
10.3 Terumo Medical Corporation 76
10.3.1 Overview 76
10.3.2 Product/Business Segment Overview 76
10.3.3 Financial Updates 76
10.3.4 Key Developments 77
10.3.5 SWOT Analysis 78
10.4 Bayer AG 79
10.4.1 Overview 79
10.4.2 Product/Business Segment Overview 79
10.4.3 Financial Updates 79
10.4.4 Key Developments 80
10.4.5 SWOT Analysis 81
10.5 HTL-STREFA S.A. 82
10.5.1 Company Overview 82
10.5.2 Product/Business Segment Overview 82
10.5.3 Financial Updates 83
10.5.4 Key Development 83
10.5.5 SWOT Analysis 83
10.6 Sarstedt AG & Co. 84
10.6.1 Overview 84
10.6.2 Product/Business Segment Overview 84
10.6.3 Financial Overview 84
10.6.4 SWOT Analysis 85
10.7 Improve Medical Technology Co. Ltd 86
10.7.1 Overview 86
10.7.2 Product/Business Segment Overview 86
10.7.3 Financial Updates 86
10.7.4 SWOT Analysis 86